Literature DB >> 15211006

A retrospective examination of reinfection of humans with Plasmodium vivax.

William E Collins1, Geoffrey M Jeffery, Jacquelin M Roberts.   

Abstract

A retrospective examination was made of archival data collected between 1940 and 1963 to determine the impact of reinfection of patients with Plasmodium vivax with homologous and heterologous strains of the parasite. Following reinfection of 14 patients with a homologous strain, the geometric mean maximum parasite count was reduced from 9,101/microL during the primary infection to 998/microL and the geometric mean daily parasite count for the first 20 days was reduced from 923/microL to 16/microL. Following reinfection of 22 patients with heterologous strains of P. vivax, the geometric mean maximum parasite count was 8,460/microL during the primary infection versus a secondary level of 9,196/microL and the geometric mean daily parasite count decreased from 847/microL/day to 335/microL/day. Reductions in fever episodes > or =101 degrees F and > or = 104 degrees F appeared to be a more sensitive measure of clinical immunity. Fever episodes > or =104 degrees F in patients with homologous strain reinfections decreased from 1.92 episodes per week to 0.18 compared with 1.24 to 0.57 in patients with heterologous infections. Fever episodes > or =101 degrees F decreased from 2.98 to 0.60 in the homologous strain compared with 2.08 to 1.07 for the heterologous infections. The average maximum fever temperature in the homologous group was 106 degrees F during the primary infection versus 103.4 degrees F for the secondary infection compared with 105.8 degrees F during the primary infections versus 105.6 degrees F for the secondary infection in the heterologous patients.

Entities:  

Mesh:

Year:  2004        PMID: 15211006

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  26 in total

1.  Prevention and treatment of vivax malaria.

Authors:  J Kevin Baird; Eli Schwartz; Stephen L Hoffman
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

Review 2.  Imported Malaria in Countries where Malaria Is Not Endemic: a Comparison of Semi-immune and Nonimmune Travelers.

Authors:  Johannes Mischlinger; Caroline Rönnberg; Míriam J Álvarez-Martínez; Silja Bühler; Małgorzata Paul; Patricia Schlagenhauf; Eskild Petersen; Michael Ramharter
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

Review 3.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

4.  Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children.

Authors:  Jennifer L Cole-Tobian; Pascal Michon; Moses Biasor; Jack S Richards; James G Beeson; Ivo Mueller; Christopher L King
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

5.  Origin of the St. Elizabeth strain of Plasmodium vivax.

Authors:  William Collins
Journal:  Am J Trop Med Hyg       Date:  2013-01-28       Impact factor: 2.345

6.  Mosquito Bite-Induced Controlled Human Malaria Infection with Plasmodium vivax or P. falciparum Generates Immune Responses to Homologous and Heterologous Preerythrocytic and Erythrocytic Antigens.

Authors:  Cysha E Hall; Lisa M Hagan; Elke Bergmann-Leitner; Donna M Tosh; Jason W Bennett; Jason A Regules; Ilin Chuang; Evelina Angov; Sheetij Dutta; Debasish Chattopadhyay; Anjali Yadava
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

7.  Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children.

Authors:  Enmoore Lin; Benson Kiniboro; Laurie Gray; Stuart Dobbie; Leanne Robinson; Annemarie Laumaea; Sonja Schöpflin; Danielle Stanisic; Inoni Betuela; Melinda Blood-Zikursh; Peter Siba; Ingrid Felger; Louis Schofield; Peter Zimmerman; Ivo Mueller
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

Review 8.  Vivax malaria: neglected and not benign.

Authors:  Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

Review 9.  Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection.

Authors:  Ivo Mueller; Vasee S Moorthy; Graham V Brown; Peter G Smith; Pedro Alonso; Blaise Genton
Journal:  Vaccine       Date:  2009-07-26       Impact factor: 3.641

Review 10.  Acquired immunity to malaria.

Authors:  Denise L Doolan; Carlota Dobaño; J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.